Document is current
Any future updates will be listed below
-
Authors
Drwiega, Emily N.
Rodvold, Keith A. https://orcid.org/0000-0002-7200-7346
- License Information
-
More Information
Article History
Accepted: 29 November 2021
First Online: 4 January 2022
Declarations
:
: This response was not funded in whole or in part by any research grant or funding body.
: Emily Drwiega has no conflicts of interest that are directly relevant to the content of this letter. Keith Rodvold has conducted research and/or served as a consultant for intrapulmonary studies discussed in this letter for Cempra Pharmaceuticals, Cubist Pharmaceuticals, Durata Therapeutics, Entasis Therapeutics, GlaxoSmithKline, Ortho-McNeil Pharmaceutical, Paretek Pharmaceuticals, Shionogi & Co., The Medicine Company/Rempex, and Wockhardt Ltd. Keith Rodvold has served on advisory boards, speaking bureaus, or as a consultant for Merck Inc., Shionogi & Co., Sinovent, Spero Therapeutics, The Medicine Company/Qpex Biopharma, and Venatorx Pharmaceuticals.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Both authors made substantial contributions to the conception, drafting, and critically revising of the manuscript for important intellectual content. Both authors approved the final version of the manuscript.
